Ann Lab Med.  2015 Mar;35(2):226-232. 10.3343/alm.2015.35.2.226.

Quantitative Measurement of Serum MicroRNA-21 Expression in Relation to Breast Cancer Metastasis in Chinese Females

Affiliations
  • 1Department of Laboratory Medicine, The First Hospital of Zibo City, Zibo, China. wguinian@163.com
  • 2Department of Pharmacy, Zibo Vocational Institute, Zibo, China.
  • 3Department of Surgical Medicine, The First Hospital of Zibo City, Zibo, China.
  • 4Key Laboratory of Biomedical Engineering, Shandong Wanjie Medical College, Zibo, China.

Abstract

BACKGROUND
Breast cancer is the most common type of cancer in females. Aberrant expression of microRNA-21 (miR-21) has previously been reported in breast cancer tissue. The aim of this study was to investigate expression levels of serum miR-21 in breast cancer patients and evaluate its prognostic value in Chinese females.
METHODS
Real-time quantitative (RQ)-PCR was used to analyze miR-21 expression in archived serum, tumor tissue, and adjacent normal tissue from 549 participants (326 with breast cancer, 223 without breast cancer). We also analyzed associations between serum miR-21 expression and breast cancer subtypes and patient prognosis. Recurrence and survival were analyzed by using the multivariate Cox proportional hazards model.
RESULTS
Expression of miR-21 was significantly higher in breast cancer tissues compared with normal adjacent breast tissues (P<0.001). The 2(-DeltaDeltaCt) values for serum miR-21 in breast cancer patients versus healthy controls were 9.12+/-3.43 and 2.96+/-0.73, respectively. Multivariate Cox proportional hazards model suggested that serum miR-21 expression was an independent poor prognostic factor for both recurrence (hazard ratio [HR]= 2.942; 95% confidence interval [CI]=1.420-8.325; P=0.008) and disease-free survival (HR=2.732; 95% CI=1.038-7.273, P=0.003) in breast cancer.
CONCLUSIONS
Increased serum miR-21 expression level was correlated with poor prognosis of breast cancer patients, indicating that serum miR-21 may be a novel prognostic marker for recurrence and survival of breast cancer patients before resection.

Keyword

Biomarker; Breast cancer; Prognosis; Serum miR-21

MeSH Terms

Biomarkers, Tumor/genetics
Breast/metabolism
Breast Neoplasms/metabolism/mortality/*pathology
Disease-Free Survival
Female
Humans
Kaplan-Meier Estimate
Lymphatic Metastasis
MicroRNAs/*blood
Neoplasm Recurrence, Local
Prognosis
Proportional Hazards Models
Real-Time Polymerase Chain Reaction
Biomarkers, Tumor
MicroRNAs
Full Text Links
  • ALM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr